Lipoprotein-Associated Phospholipase A2 Activity
LP-PLA2 A
Description
"Lipoprotein-Associated Phospholipase A2 Activity" test evaluates how active this inflammation-related enzyme is within your blood vessels. Increased activity levels are associated with higher risk of atherosclerosis, heart attack, or stroke. It’s particularly helpful for patients with metabolic syndrome or a family history of cardiovascular disease. Results help doctors develop preventive plans such as medications, dietary shifts, or other interventions. Tracking enzyme activity over time can provide deeper insight into plaque stability and help reduce future cardiac complications.
Category
Enzymes
Procedure
Invasive
Sample Type
Blood – Serum
Units
Nanomoles Per Minute Per Milliliter
Procedure Category
Blood Draw
Test Group
Basic Cardiovascular Group, Complete Cardiovascular Group, Cardio Risk Group, Enzyme Group, Complete Inflammation Group
Test Group Description
Basic Cardiovascular Group: This group includes fundamental tests targeting essential markers related to cardiovascular health, providing foundational insights into cholesterol levels, blood pressure, and other key factors. Cardio Risk Group: This group focuses on assessing various markers associated with cardiovascular health and risk factors, aiding in the early detection and management of cardiovascular diseases. Complete Cardiovascular Group: This group contains comprehensive tests for an extensive evaluation of cardiovascular health, providing thorough insights into heart-related conditions beyond basic assessments. Complete Inflammation Group: Extensive tests offer a comprehensive assessment of inflammatory markers, yielding detailed insights into inflammation levels and related health conditions. Enzyme Group: Evaluates enzyme levels and activity, offering insights into enzymatic function and related health conditions.
Optimal Range
For All Individuals:
Conventional Unit: <75.00 nmol/min/mL
SI Unit: <75.00 nmol/min/mL
Normal Range
For All Individuals:
Conventional Unit: ≤123.00 nmol/min/mL
SI Unit: ≤123.00 nmol/min/mL
Results That Differ From The Norm (Direct and Indirect Causes)
Increased levels may indicate:
Atherosclerosis (Build-up of plaque in arteries)
Coronary artery disease (Narrowing or blockage of coronary arteries)
Genetic factors (Inherited traits influencing lipoprotein-associated phospholipase A2 levels)
Ischemic stroke (Stroke caused by blocked blood flow to the brain)
Metabolic syndrome (cluster of conditions in...
Key Reasons For Testing
Cardiovascular Risk Assessment: Identifies vascular inflammation to evaluate heart attack and stroke risk.
Evaluation of Atherosclerosis: Detects and monitors atherosclerotic plaque development.
Identification of High-Risk Patients: Stratifies cardiovascular risk for targeted prevention.
Assessment of Plaque Stability: Evaluates risk of plaque rupture and thrombosis.
Monitoring Response to Therapy: Tracks effectiveness of lipid-lowering treatments.
Health Status Conditions It May Be Used To Assess
Currently, this test is not directly associated with any conditions listed on the Health Status page. However, it may be included as part of a broader set of tests linked to specific health conditions.
Some Prominent Medical Labs That May Offer This Test
Please note that this particular test has not been associated with any of the listed prominent medical labs. We recommend enquiring with your private physician or nearest hospital to determine where this specific test can be performed.
References
Important Note
Any medical procedure yielding results outside the norm may be directly or indirectly linked to the conditions outlined on this page. Various factors, including genetics, medication and supplement usage, recent illnesses, pregnancy, pre-test eating, smoking, and stress, can impact the test's outcome. Additionally, factors like false positives, false negatives, inaccurate analyses, and others can influence results.
Reference ranges, which help healthcare professionals interpret medical tests, may vary depending on age, gender, and other factors. They may also differ between laboratories due to variations in instruments and methods used. Optimal ranges are designed for preventive purposes, aiming to identify trends and potential risks early, while normal ranges reflect conventional laboratory values indicating no current disease or pathology. Your healthcare practitioner may have specific reasons for testing that deviate from the usual or may interpret results differently based on individual circumstances. Proper interpretation typically involves considering clinical findings and other diagnostic tests. Hence, it is crucial to provide your healthcare professionals with a comprehensive medical history, consult with them for result interpretation, and follow their guidance for potential re-testing or additional diagnostics.
Disclaimer
This content is provided solely for informative and educational purposes. It is not intended as a substitute for medical advice or treatment from a personal physician. Regarding the interpretation of their medical test results and/or specific health questions, it is recommended that all readers and viewers consult their physicians or other qualified health professionals. The publisher is not responsible for any adverse health effects that may result from reading or following the information in this educational content. Before beginning any nutrition, supplement, or lifestyle program, all viewers, especially those taking prescription or over-the-counter medications, should consult their physician or health care practitioner.
Please note that while prominent lab names are included in this content, we cannot guarantee that these labs offer all the tests mentioned. For confirmation, individuals should contact the labs directly or consult their medical practitioners. The information provided reflects general knowledge at the time of publication and may not include recent updates or emerging research. Readers should verify details with qualified professionals to ensure the most up-to-date and accurate guidance.
[1] Brilakis ES, McConnell JP, Lennon RJ, Elesber AA, Meyer JG, Berger PB. Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J. 2005;26(2):137-144.
[2] Packard CJ, O'Reilly DS, Caslake MJ, et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. N Engl J Med. 2000;343(16):1148-1155.
[3] Ballantyne CM, Hoogeveen RC, Bang H, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2004;109(7):837-842.
[4] Koenig W, Khuseyinova N, Löwel H, Trischler G, Meisinger C. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort study. Circulation. 2004;110(14):1903-1908.
[5] Tselepis AD, John Chapman M. Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. Atheroscler Suppl. 2002;3(4):57-68.
[6] Rosenson RS, Stafforini DM. Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2. J Lipid Res. 2012;53(9):1767-1782.
[7] Blake GJ, Dada N, Fox JC, Manson JE, Ridker PM. A prospective evaluation of lipoprotein-associated phospholipase A2 levels and the risk of future cardiovascular events in women. J Am Coll Cardiol. 2001;38(5):1302-1306.
[8] Mohler ER III, Ballantyne CM, Davidson MH, et al. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalents: the results of a multicenter, randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 2008;51(17):1632-1641.
[9] O'Donoghue ML, Morrow DA, Sabatine MS, et al. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial. Circulation. 2006;113(14):1745-1752.
[10] Zalewski A, Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol. 2005;25(5):923-931.
[11] Caslake MJ, Packard CJ. Lipoprotein-associated phospholipase A2 as a biomarker of coronary heart disease: evidence and future roles. Curr Opin Lipidol. 2005;16(4):344-348.
[12] Corson MA. Darapladib and atherosclerotic plaque stabilization. Curr Vasc Pharmacol. 2010;8(5):627-635.
[13] Macphee CH, Moores KE, Boyd HF, et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates oxidized non-esterified fatty acids in oxidized low-density lipoprotein that are toxic to human macrophages. Biochem J. 1999;342(Pt 1):27-35.
[14] Wolfert RL, Tan L, Forsythe LK, Otvos JD. Lipoprotein-associated phospholipase A2: a novel biomarker for cardiovascular risk assessment. Clin Chem. 2007;53(2):323-331.
[15] Kolodgie FD, Burke AP, Skorija KS, et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 2006;26(11):2523-2529.
[16] Cojocaru M, Cojocaru IM, Silosi I. Lipoprotein-associated phospholipase A2 as a predictive biomarker of sub-clinical inflammation in cardiovascular diseases. Maedica (Bucur). 2010;5(1):51-55.